GLP-1 Prescriptions for Children Now Begin at Age 10 for Diabetes Cases
Doctors in Louisiana report that weight loss injectables are being prescribed to young patients when lifestyle changes fail, with cost remaining a primary barrier for families.
By Sanjay Caldwell ·
Dr. Rhea Rogers, a board-certified physician and host of the television program Aging Untold, stated that weight loss medications known as GLP-1s are now being prescribed to some children in the United States. These drugs, which have gained widespread popularity among adults, are entering the pediatric market as a treatment option for specific medical conditions.
According to Rogers, healthy eating and exercise do not always result in weight loss for young patients. She explained that genetic factors can limit the effectiveness of lifestyle changes alone. When a child becomes significantly overweight, it can lead to hormonal dysregulation, which requires medical intervention beyond diet and activity.
Rogers described GLP-1 agonists as effective tools for addressing these physiological issues. She noted that the medications help reduce what she called food noise and food chatter. She also described the drugs as anti-inflammatory, suggesting they provide assistance to patients who struggle with hormonal imbalances that standard lifestyle adjustments cannot correct.
Experts cited in the report identified specific criteria for pediatric candidates. For patients with diabetes, the minimum age for prescribing these medications can be as low as 10 years old. For weight loss purposes, the ideal candidate is typically a child with a body mass index at or above the 95th percentile. These patients must have already attempted lifestyle changes without success and may have developed hormone problems that necessitate drug therapy.
Rogers emphasized that the medication is not a standalone solution. She described it as a tool within a larger treatment plan, stating that providers must treat the entire scenario rather than relying on the drug alone. This approach integrates the medication with other health management strategies for the child.
The cost of GLP-1s remains a major obstacle for many families. For patients who cannot afford the medication or who choose not to take it, the current recommendation is to maintain well-balanced meals and adopt a healthy lifestyle. This financial barrier continues to influence treatment decisions for pediatric patients across the region.
Students at Magnolia Woods Elementary in Baton Rouge, Louisiana, are participating in a statewide initiative to lower obesity rates. The program focuses on teaching children about healthy eating and exercise, providing a foundation for health management before medical interventions like GLP-1 prescriptions are considered.
